The global bleeding disorders treatment market is projected to reach USD 20.80 Billion by 2027 from USD 14.13 Billion in 2020, at a CAGR of 5.7 % from 2020 to 2027. Bleeding disorder is a medical condition characterized by the improper functioning of blood clotting process called as coagulation. Body’s coagulation system is unable to form blood clots at the site of injury, at incisions made during surgery, trauma or menstruation which results in moderate to high levels of blood loss. Most of bleeding disorders are inherited. It is also acquired with some liver diseases, side effects of certain medications, low red blood cell count, and vitamin K deficiency. There are three main types of this condition: haemophilia, clotting factor deficiency, and Von Willebrand Disease (VWD). Treatment of bleeding disorder depends on the severity and type of disorder. Various treatment options are available for bleeding disorder such as replacement therapies which include clotting factor replacement, fresh frozen plasma transfusion, platelet transfusion, iron supplementation, and medication treatments.
The growing prevalence of bleeding disorders globally will act as a primary driver for the growth of the bleeding disorder treatment market. The majority of bleeding conditions are inherited but some are acquired due to side effects of certain medications, vitamin K deficiency, liver diseases, low red blood cell count, and others. The rising incidences of causative factors leading to bleeding disorder will stimulate the demand for treatment over the forecast timeframe.
The increasing number of people suffering from anaemia, liver diseases, and blood coagulating conditions will drive bleeding disorder treatment market size. Increasing awareness about bleeding conditions, especially haemophilia, coupled with numerous government initiatives to establish a wide network of bleeding disorder diagnosis and treatment centres will support industry expansion over the coming years.
High investments in R&D activities pertaining to the development of recombinant factors along with improvements in the technology used for treating bleeding conditions will drive industry growth over the forecast period. However, the shortage of skilled healthcare professionals and the high cost of medications will restrain industry growth to a certain extent over the coming years.
The key players in the bleeding disorders treatment market are Shire Plc. (earlier Baxalta) (Ireland), Bayer AG (Germany), Biogen Inc. (U.S.), CSL Behring (U.S.), Novo Nordisk (Denmark), Pfizer Inc. (U.S.), and Grifols SA (Spain).
The market in North America is expected to dominate in the global market and is expected to continue its dominance over the forecast period. This can be attributed to well-developed healthcare facilities, favourable regulatory scenario, and presence of major players operating in the countries in this region. In addition, increasing strategic expansion activities through merger and agreement is expected to further support growth of the target market in this region over the forecast period.
The market in Asia Pacific is expected to witness faster growth, owing to increasing government expenditure on healthcare sector, developing healthcare regulations, and presence of prominent players operating in emerging economies such as China and India in the region.
Report : Bleeding Disorders Treatment Market - By Type (Haemophilia A, Haemophilia B, vWD, and Others), By Drug Class (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, And Others) And By Region (North America, Asia Pacific, Europe, Middle East & Africa and Latin America) - Industry Analysis, opportunity and Forecast 2020 To 2027